Press Release: Aclipse Therapeutics Awarded AUD 1 Million Grant from FightMND | BusinessWire

Gordian Life Sciences Leads a $6mm Series A Preferred Raise

Aclipse Therapeutics announces $1mm AUD grant from leading research fund in fight against ALS. Series A financing round to fund clinical studies remains open for interested parties


Aclipse Therapeutics was awarded a US$720,000 drug development grant from FightMND for the development of M102, a targeted therapy for Amyotrophic Lateral Sclerosis (ALS)

RADNOR, Pa.–(BUSINESS WIRE)–Aclipse Therapeutics, a private Pennsylvania biopharmaceutical company, was awarded an AUD 1 million (approximately US $720,000) drug development research grant from FightMND, the largest independent funder of ALS research in Australia. The grant will support the translational development of M102, a drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig’s disease. M102 showed promise to stop and reverse ALS disease progression, as evidenced by data in preclinical models. Currently, there is no cure for ALS and no effective treatments to halt or reverse the progression of this devastating disease.

“We are very excited for ALS/MND patients, as FightMND is supporting our effort to advance this important therapy, which looks so promising in preclinical models, into clinical trials for our patients,” said Professor Dame Pamela Shaw MD, a primary contributor to M102’s development program. Professor Shaw is Professor of Neurology and the Director of the Sheffield Institute for Translational Neuroscience (SITraN) at the University of Sheffield (UK). Professor Shaw and her SITraN colleagues Dr. Richard Mead and Dr. Laura Ferraiuolo have led the key ALS/MND biology research and drug discovery of M102, as a fruition of their commitment and dedication to push the frontiers of science in ALS/MND for the benefit of patients over the last 20 years.

Read full press release HERE